Alterity Therapeutics (NASDAQ:ATHE) Coverage Initiated by Analysts at Maxim Group

Maxim Group assumed coverage on shares of Alterity Therapeutics (NASDAQ:ATHE) in a report issued on Thursday, MarketBeat Ratings reports. The firm issued a buy rating and a $8.00 price objective on the stock.

Alterity Therapeutics Stock Up 5.0 %

ATHE opened at $2.33 on Thursday. Alterity Therapeutics has a 1 year low of $1.00 and a 1 year high of $3.25. The firm’s fifty day moving average price is $1.34 and its two-hundred day moving average price is $1.50.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.